These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21940407)

  • 21. Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (Fostera™ PCV MH) under experimental conditions.
    Park C; Jeong J; Choi K; Chae C
    Vaccine; 2016 Jan; 34(2):270-275. PubMed ID: 26626212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b.
    Jeong J; Park C; Choi K; Chae C
    Vet Microbiol; 2015 May; 177(1-2):43-52. PubMed ID: 25790733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing PCV2 antibodies in field pigs vaccinated with different porcine circovirus 2 vaccines using two commercial ELISA systems.
    Shin MK; Yoon SH; Kim MH; Lyoo YS; Suh SW; Yoo HS
    J Vet Sci; 2015; 16(1):25-9. PubMed ID: 25234326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of sow and/or piglet vaccination of 3 commercial porcine circovirus type 2 (PCV2) single-dose vaccines on pigs under experimental PCV2 challenge.
    Oh Y; Seo HW; Park C; Chae C
    Vet Microbiol; 2014 Aug; 172(3-4):371-80. PubMed ID: 24970364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective humoral immunity in guinea pigs induced by PCV2 virus-like particles displaying the B cell linear epitope (
    Wang N; Zhang S; Wang D; Li F; Liang L; Li X; Zou Y; Zhan Y; Chen G; Yu W; Deng Z; Tu D; Cui S
    Vet Microbiol; 2019 Aug; 235():86-92. PubMed ID: 31282383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective efficacy of a virus-vectored multi-component vaccine against porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 and swine influenza virus.
    Tian D; Sooryanarain H; Matzinger SR; Gauger PC; Karuppannan AK; Elankumaran S; Opriessnig T; Meng XJ
    J Gen Virol; 2017 Dec; 98(12):3026-3036. PubMed ID: 29091579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions.
    Opriessnig T; Xiao CT; Halbur PG; Gerber PF; Matzinger SR; Meng XJ
    Vaccine; 2017 Jan; 35(2):248-254. PubMed ID: 27919634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of single dose of an inactivated porcine circovirus type 2 (PCV2) whole-virus vaccine with oil adjuvant in piglets.
    Yang K; Li W; Niu H; Yan W; Liu X; Wang Y; Cheng S; Ku X; He Q
    Acta Vet Scand; 2012 Nov; 54(1):67. PubMed ID: 23171757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of Postweaning Multisystemic Wasting Syndrome-Associated Clinical Symptoms by Virus-Like Particle Vaccine Against Porcine Parvovirus and Porcine Circovirus Type 2.
    Liu G; Qiao X; Chang C; Hua T; Wang J; Tang B; Zhang D
    Viral Immunol; 2020; 33(6):444-456. PubMed ID: 32255758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of porcine parvovirus vaccination on the development of PMWS in segregated early weaned pigs coinfected with type 2 porcine circovirus and porcine parvovirus.
    Opriessnig T; Fenaux M; Yu S; Evans RB; Cavanaugh D; Gallup JM; Pallares FJ; Thacker EL; Lager KM; Meng XJ; Halbur PG
    Vet Microbiol; 2004 Mar; 98(3-4):209-20. PubMed ID: 15036529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition.
    Trible BR; Ramirez A; Suddith A; Fuller A; Kerrigan M; Hesse R; Nietfeld J; Guo B; Thacker E; Rowland RR
    Vaccine; 2012 Jun; 30(27):4079-85. PubMed ID: 22521847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of porcine circovirus type 2 vaccination in reducing the severity of post-weaning multisystemic wasting syndrome in pigs.
    Velasova M; Alarcon P; Werling D; Nevel A; Wieland B
    Vet J; 2013 Sep; 197(3):842-7. PubMed ID: 23830301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Porcine circovirus type 2 infection decreases the efficacy of a modified live porcine reproductive and respiratory syndrome virus vaccine.
    Opriessnig T; McKeown NE; Harmon KL; Meng XJ; Halbur PG
    Clin Vaccine Immunol; 2006 Aug; 13(8):923-9. PubMed ID: 16893993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of maternal antibodies on efficacy of porcine circovirus type 2 (PCV2) vaccination to protect pigs from experimental infection with PCV2.
    Opriessnig T; Patterson AR; Elsener J; Meng XJ; Halbur PG
    Clin Vaccine Immunol; 2008 Mar; 15(3):397-401. PubMed ID: 18094109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporation of ORF2 from Porcine Circovirus Type 2(PCV2) into genetically encoded nanoparticles as a novel vaccine using a self-aggregating peptide.
    Zepeda-Cervantes J; Cruz-Reséndiz A; Sampieri A; Carreón-Nápoles R; Sánchez-Betancourt JI; Vaca L
    Vaccine; 2019 Mar; 37(14):1928-1937. PubMed ID: 30824359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of cell-mediated immune responses against porcine circovirus type 2 (PCV2) Cap and Rep proteins after vaccination with a commercial PCV2 sub-unit vaccine.
    Fort M; Sibila M; Nofrarías M; Pérez-Martín E; Olvera A; Mateu E; Segalés J
    Vet Immunol Immunopathol; 2012 Nov; 150(1-2):128-32. PubMed ID: 23010221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate.
    Lamazares E; Gutiérrez F; Hidalgo A; Gutiérrez NA; Espinoza FI; Sánchez O; Cortez-San Martín M; Mascayano C; González J; Saavedra J; Altamirano C; Mansur M; Ruiz Á; Toledo JR
    Viruses; 2020 Mar; 12(4):. PubMed ID: 32244384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV).
    Shen HG; Beach NM; Huang YW; Halbur PG; Meng XJ; Opriessnig T
    Vaccine; 2010 Aug; 28(37):5960-6. PubMed ID: 20637768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Best practice and future challenges for vaccination against porcine circovirus type 2.
    Segalés J
    Expert Rev Vaccines; 2015 Mar; 14(3):473-87. PubMed ID: 25400216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination with a Porcine Reproductive and Respiratory Syndrome (PRRS) Modified Live Virus Vaccine Followed by Challenge with PRRS Virus and Porcine Circovirus Type 2 (PCV2) Protects against PRRS but Enhances PCV2 Replication and Pathogenesis Compared to Results for Nonvaccinated Cochallenged Controls.
    Niederwerder MC; Bawa B; Serão NV; Trible BR; Kerrigan MA; Lunney JK; Dekkers JC; Rowland RR
    Clin Vaccine Immunol; 2015 Dec; 22(12):1244-54. PubMed ID: 26446422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.